Regulators Moving Ahead Of Industry In China? Officials, Execs Weigh In
Shorter INDs But Trial Delays
While regulators are steaming ahead to accelerate clinical trial and product approvals, China's pharma industry still lacks innovation. Underlying the hot investment, multi-million deals and IPOs is a lingering reliance on 'fast-following,' regulators and pharma execs tell the DIA China meeting.
You may also be interested in...
The nation’s top drug regulator vows to adopt ICH’s guidelines on drug safety and efficacy, after dropping the industry a bombshell with the tightening of oncology drug clinical trials a week ago.
Three years since the first cluster of SARS-CoV-2 infections were reported in Wuhan, China has finally put the first nail in the coffin of its strict "COVID Zero" policies. But as Beijing begins to relax its most restrictive rules, citizens remain concerned about ballooning infections, while a low vaccination rate among seniors and vaccine fatigue appear to be dimming hopes of a quick revitalization of the hard-hit economy and bruised consumer confidence.
One well-connected individual registered as many as 35 nucleic testing firms within just a few months, all of which are strategically located in the Chinese cities that have seen some of the worst COVID-19 flareups. Meanwhile, regulators have halted the IPOs of 13 companies.